228
Participants
Start Date
January 7, 2016
Primary Completion Date
January 13, 2020
Study Completion Date
January 13, 2020
Atezolizumab
Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) by intravenous (IV) infusion.
RO6958688
"RO6958688 is administered by IV infusion~In Part IA: RO6958688 is administered weekly (QW) on days 1,8 and 15 of each 21-day cycle.~In Part 1b: RO6958688 is administered weekly (QW) or every 3 weeks (Q3W). Cohort A: RO6958688 starting dose will be 100 mg either QW or Q3W.~Step Up dose cohorts: RO6958688 starting dose will be 40mg and increase with each administration up to the MTD or 1200 mg whichever is lower."
Rigshospitalet; Onkologisk Klinik, København Ø
Columbia Univ Med Ctr, New York
Memorial Sloan Kettering Cancer Center, New York
Duke Cancer Center, Durham
START Madrid-FJD, Hospital Fundacion Jimenez Diaz, Madrid
Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid
START Madrid. Centro Integral Oncologico Clara Campal; CIOCC, Madrid
Medical University of South Carolina, Charleston
Clinica Universitaria de Navarra; Servicio de Oncologia, Pamplona
Sarah Cannon Cancer Center, Germantown
Azienda Ospedaliera Universitaria Senese, U.O.C. Immunoterapia Oncologica, Siena
Centre Leon Berard; Departement Oncologie Medicale, Lyon
MD Anderson Cancer Center, Houston
University Of Colorado, Aurora
IRCCS IST. Tumori Fondaz. Pascale; S.C. Oncologia Medica,Melanoma,Immunoterapia E Terapie Innovative, Napoli
UCLA Cancer Center, Santa Monica
Stanford Comprehensive Cancer Center, Stanford
Institut Gustave Roussy, Villejuif
Smilow Cancer Hospital at Yale- New Haven Oncology Investigational Drug Pharmacy, New Haven
Dana Farber Can Ins, Boston
Princess Margaret Cancer Center, Toronto
Antoni Van Leeuwenhoek Ziekenhuis; Gastro-Enterologie, Amsterdam
Hospital del Mar; Servicio de Oncologia, Barcelona
Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona
Hoffmann-La Roche
INDUSTRY